Antiretroviral agents and prevention of malaria in HIV-infected ugandan children

New England Journal of Medicine

Volumn 367, Issue 22, 2012, Pages 2110-2118

  Achan, Jane ^a   Kakuru, Abel ^a   Ikilezi, Gloria ^a   Ruel, Theodore ^b   Clark, Tamara D ^b   Nsanzabana, Christian ^b   Charlebois, Edwin ^b   Aweeka, Francesca ^c   Dorsey, Grant ^b   Rosenthal, Philip J ^b   Havlir, Diane ^b   Kamya, Moses R ^a  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; EFAVIRENZ; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE;

ADVERSE OUTCOME; ANTIMALARIAL DRUG SUSCEPTIBILITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PARASITE CLEARANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RECURRENCE RISK; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRUS INFECTIVITY;

EID: 84870040443     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1200501     Document Type: Article

References (23)

1. Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim- sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 2007;21:2059-66. (Pubitemid 47462155)
2. Nsanzabana C, Rosenthal PJ. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob Agents Chemother 2011;55:5073-7.
3. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2005;49:2983-5. (Pubitemid 40917621)
4. Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretrovirals as antimalarial agents. J Infect Dis 2004;190:1998-2000. (Pubitemid 39564706)
5. Andrews KT, Fairlie DP, Madala PK, et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother 2006;50:639-48. (Pubitemid 43190977)
6. German P, Parikh S, Lawrence J, et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009;51:424-9.
7. Okello PE, Van Bortel W, Byaruhanga AM, et al. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 2006;75:219-25. (Pubitemid 46941334)
8. Susceptibility of Plasmodium falciparum to antimalarial drugs: report on global monitoring: 1996-2004. Geneva: World Health Organization, 2005.
9. Table for grading the severity of adult and pediatric adverse events. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 2004 (http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/ daidsaegradingtable.pdf).
10. Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007;297:2210-9.
11. Huang L, Li X, Marzan F, Lizak PS, Aweeka FT. Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis 2012;4:157-66.
12. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother 2010;54:1200-6.
13. François G, Hendrix L, Wery M. A highly efficient in vitro cloning procedure for asexual erythrocytic forms of the human malaria parasite Plasmodium falciparum. Ann Soc Belg Med Trop 1994;74:177-85.
14. Lek-Uthai U, Suwanarusk R, Ruengweerayut R, et al. Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob Agents Chemother 2008;52:2435-41. (Pubitemid 351915673)
15. Redmond AM, Skinner-Adams T, Andrews KT, et al. Antimalarial activity of sera from subjects taking HIV protease inhibitors. AIDS 2007;21:763-5. (Pubitemid 46568635)
16. Nathoo S, Serghides L, Kain KC. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet 2003;362:1039-41. (Pubitemid 37186882)
17. Mwesigwa J, Parikh S, McGee B, et al. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother 2010;54:52-9.
18. van Vugt M, Ezzet F, Nosten F, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 1999;61:964-7. (Pubitemid 30084122)
19. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother 2006;50:1893-5.
20. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010;363:1510-20.
21. Palumbo PVA. NVP- vs LPV/r-based ART among HIV+ infants in resource limited settings: the IMPAACT1060 trial. Presented at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 27-March 2, 2011. abstract.
22. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9. (Pubitemid 38072176)
23. Ashley EA, Stepniewska K, Lindegårdh N, et al. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop Med Int Health 2007;12:201-8.